43 related articles for article (PubMed ID: 37160694)
1. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
2. Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells.
Pan ST; Qin Y; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Zhou SF; Qiu JX
Drug Des Devel Ther; 2015; 9():5511-51. PubMed ID: 26491260
[TBL] [Abstract][Full Text] [Related]
3. β
Mele L; Del Vecchio V; Marampon F; Regad T; Wagner S; Mosca L; Bimonte S; Giudice A; Liccardo D; Prisco C; Schwerdtfeger M; La Noce M; Tirino V; Caraglia M; Papaccio G; Desiderio V; Barbieri A
Cell Death Dis; 2020 Oct; 11(10):850. PubMed ID: 33051434
[TBL] [Abstract][Full Text] [Related]
4. NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma.
Hamad SH; Sellers RS; Wamsley N; Zolkind P; Schrank TP; Major MB; Weissman BE
Cancer Res Commun; 2024 Feb; 4(2):487-495. PubMed ID: 38335300
[TBL] [Abstract][Full Text] [Related]
5. Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function.
Takahashi J; Suzuki T; Sato M; Nitta S; Yaguchi N; Muta T; Tsuchida K; Suda H; Morita M; Hamada S; Masamune A; Takahashi S; Kamei T; Yamamoto M
Cell Rep; 2024 Apr; 43(4):114104. PubMed ID: 38602872
[TBL] [Abstract][Full Text] [Related]
6. NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells.
Guan L; Nambiar DK; Cao H; Viswanathan V; Kwok S; Hui AB; Hou Y; Hildebrand R; von Eyben R; Holmes BJ; Zhao J; Kong CS; Wamsley N; Zhang W; Major MB; Seol SW; Sunwoo JB; Hayes DN; Diehn M; Le QT
Cancer Res; 2023 Mar; 83(6):861-874. PubMed ID: 36652552
[TBL] [Abstract][Full Text] [Related]
7. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
Yu W; Chen Y; Putluri N; Osman A; Coarfa C; Putluri V; Kamal AHM; Asmussen JK; Katsonis P; Myers JN; Lai SY; Lu W; Stephan CC; Powell RT; Johnson FM; Skinner HD; Kazi J; Ahmed KM; Hu L; Threet A; Meyer MD; Bankson JA; Wang T; Davis J; Parker KR; Harris MA; Baek ML; Echeverria GV; Qi X; Wang J; Frederick AI; Walsh AJ; Lichtarge O; Frederick MJ; Sandulache VC
Br J Cancer; 2023 Jun; 128(11):2013-2024. PubMed ID: 37012319
[TBL] [Abstract][Full Text] [Related]
8. Integrative radiogenomic profiling of squamous cell lung cancer.
Abazeed ME; Adams DJ; Hurov KE; Tamayo P; Creighton CJ; Sonkin D; Giacomelli AO; Du C; Fries DF; Wong KK; Mesirov JP; Loeffler JS; Schreiber SL; Hammerman PS; Meyerson M
Cancer Res; 2013 Oct; 73(20):6289-98. PubMed ID: 23980093
[TBL] [Abstract][Full Text] [Related]
9. Computer-assisted discovery and evaluation of potential ribosomal protein S6 kinase beta 2 inhibitors.
Yu F; Wu X; Chen W; Yan F; Li W
Comput Biol Med; 2024 Apr; 172():108204. PubMed ID: 38484695
[TBL] [Abstract][Full Text] [Related]
10. PIP4K2B Protein Regulation by NSD1 in HPV-Negative Head and Neck Squamous Cell Carcinoma.
Topchu I; Bychkov I; Roshchina E; Makhov P; Boumber Y
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539515
[TBL] [Abstract][Full Text] [Related]
11. RagD gene expression and NRF2 mutations in lung squamous cell carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Lett; 2012 Dec; 4(6):1167-1170. PubMed ID: 23226795
[TBL] [Abstract][Full Text] [Related]
12. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma.
Islam SS; Qassem K; Islam S; Parag RR; Rahman MZ; Farhat WA; Yeger H; Aboussekhra A; Karakas B; Noman ASM
Cell Death Dis; 2022 Aug; 13(8):696. PubMed ID: 35945195
[TBL] [Abstract][Full Text] [Related]
14. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
[TBL] [Abstract][Full Text] [Related]
15. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
16. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
